Cervix Vulva Cancer Subcommittee

Purpose

The NRG Oncology Cervix/Vulvar Cancer Subcommittee’s purpose is to improve the live of patients with Cervical/Vulvar cancer by designing and conducting practice-changing multi-institutional clinical trials and translational research. This committee focuses on developing and testing innovative advanced surgical, radiation oncology, and systemic (including chemotherapy and other targeted/biologic therapies) technologies for patients with gynecologic cervical/vulvar malignancies. Additionally, the committee is committed to identifying and rectifying disparities in patient outcomes within this population. 

The goals of this committee include developing national and international priorities, goals, and initiatives for the management of cervical/vulvar cancer; developing and managing currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of cervical/vulvar cancers; and, fostering the advancement of promising therapeutics in development and exploring potential translational research and biomarker development for incorporation into future clinical trials. This committee strives to develop and implement standardized procedures needed to design and conduct a research protocol within NRG while identifying potential barriers, and potential solutions to improve enrollment to NRG clinical trials in cervical/vulvar cancers, including fostering international collaboration. This committee meets four times a year, twice in-person and two virtual interim meetings.

Cervix Vulva Cancer Subcommittee Leadership

Chair

Charles ‘ Trey’ Leath, MD

Vice Chair

Jyoti Mayadev, MD

Vice Chair

Dmitriy Zamarin, MD
Core Committee Members

Core Members

  • Anne Van Arsdale
  • Diandra N. Ayala-Peacock
  • Parul Barry
  • Leslie Boyd
  • Stephen Bush
  • Christina Chu
  • Sarah Crafton
  • Corinne Doll
  • David Gaffney
  • Sharad Anant Ghamande
  • Lilian Gien
  • Scott Glaser
  • Kathy Han
  • Matthew Harkenrider
  • Christian S. Hinrichs
  • Naresh Jegadeesh
  • Lindsay M. Kuroki
  • Jayanthi Lea
  • Eric Leung
  • Lillie Lin
  • Michelle Loch
  • Mackenzie McGee
  • Loren Mell
  • Katherine G Miller
  • Tashanna Myers
  • Alexander Olawaiye
  • Krista Pfaendler
  • Allison Quick
  • Scott Richard
  • Sang Ryu
  • Ritu Salani
  • Judith Smith
  • Krishnansu S. Tewari
  • Christina Washington
  • Oladapo Yeku
  • Emi J Yoshida 

General Members

  • Agyemang Amma
  • Kevin Albuquerque
  • Joanne Alfieri
  • Jill Alldredge
  • Mohammed Arwa
  • Monica Avila 
  • Parul Barry
  • Sushil Beriwal
  • Kristen Bixel
  • Cecelia Boardman
  • Yovanni Casablanca
  • Christine Chin
  • Junzo Chino
  • Jessika Contreras
  • Allan Covens
  • Eric Donnelly
  • Brandon Dyer
  • Tony Eng
  • Denise Fabian
  • Emma Fields
  • Claire F. Friedman
  • Anthony Fyles
  • Allison Garda
  • Zahra Ghiassi-Nejad
  • Eugenia Girda
  • Allison Gockley
  • Jonathan Grant
  • Heidi Gray
  • Gordon Guo
  • Jordan A Holmes
  • Marilyn Huang
  • Amanda L Jackson
  • Anuja Jhingran
  • Mitchell Kamrava
  • Elizabeth Kidd
  • Yong Bae Kim
  • Wui-Jin Koh
  • Chrisann Kyi
  • Gary Lewis
  • Puyao Li
  • Elizabeth Lokich
  • Joseph Lucci
  • Colleen McCormick
  • Shauna M. McVorran
  • Teresa Meier
  • Kathryn Mills
  • Bradley Monk
  • Michael Montejo
  • Katherine Moxley
  • Christa Nagel
  • Elena B. Pereira
  • Lorraine Portelance
  • Tana Pradhan
  • Omar Ragab
  • Lois Ramondetta
  • Avani Rao
  • Dominique Rash
  • Jill Remick
  • Kimberly Resnick
  • Anupam Rishi
  • Tyler Robin
  • Andrea Russo
  • Jeanne Schilder
  • Rajni Sethi
  • Jessica Shank
  • Jean H Siedel
  • Travis T. Sims 
  • Sarah Sittenfeld
  • Suisu Song
  • Stephanie Sullivan
  • Meaghan Tenney
  • Deanna Teoh
  • Toms Vengaloor Thomas
  • J. Spencer Thompson
  • Jaclyn Wall
  • Ashley Weiner
  • Heather Williams
  • Anamaria Yeung
  • Jennifer Young-Pierce
  • Abigail S. Zamorano

Patient Representatives

Anne Heugel

Basia Lukaszczyk

Kimberly Williams

QOL Representatives

Dana Chase

 

Reset all column filters
Study Title Status Phase Disease Category Disease Site
GOG-0207

A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)(IND #69,656, Sponsor-GOG)

 Complete II Gynecologic [GY] Cervix
GOG-0210

A Molecular Staging Study of Endometrial Carcinoma

 Complete Other Gynecologic [GY] Uterine Corpus
GOG-0229O

A Randomized Phase II with a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer NCT #01935973

 Terminated I Gynecologic [GY] Uterine Corpus
GOG-0237

Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)

 Closed to Accrual Other Gynecologic [GY] Cervix
GOG-0263

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)

 Terminated III Gynecologic [GY] Cervix
GOG-0274 RTOG 1174

A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL

 Terminated III Gynecologic [GY] Cervix
GOG-0278

Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/<2CM) Cervical Cancer

Complete Other Gynecologic [GY] Cervix
GOG-9926

A Phase I Evaluation of Extended Field Radiation Therapy with Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women with Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes

 Terminated I Gynecologic [GY] Cervix
NRG-GY002

A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer

 Complete II Gynecologic [GY] Cervix
NRG-GY006

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

 Complete III Gynecologic [GY] Cervix
NRG-GY017

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer

 Terminated I Gynecologic [GY] Cervix
NRG-GY024

Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial

 Open to Accrual II Gynecologic [GY] Cervix
RTOG-1203

A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)

 Terminated III Gynecologic [GY] Other

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.